Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+Breast Cancer

被引：0
|
作者：
Goetz, M. P.
Reinicke, K. E.
Reid, J. M.
Suman, V. J.
Kuffel, M. J.
Safgren, S. L.
Buhrow, S. A.
Reynolds, C. A.
Jenkins, R. B.
Hawse, J. R.
Perez, E. A.
Ingle, J. N.
Ames, M. M.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：594S / 594S
页数：1
相关论文
共 50 条
  • [1] Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+Breast Cancer
    Menendez, Javier A.
    Papadimitropoulou, Adriana
    Vander Steen, Travis
    Cuyas, Elisabet
    Oza-Gajera, Bharvi P.
    Verdura, Sara
    Espinoza, Ingrid
    Vellon, Luciano
    Mehmi, Inderjit
    Lupu, Ruth
    CANCERS, 2021, 13 (05) : 1 - 19
  • [2] Endoxifen exhibits potent in vitro and in vivo antitumor activity in ER+/HER2+breast cancer and tamoxifen refractory tumors
    Reinicke, Kathryn E.
    Hou, Xiaonan
    Goetz, Matthew P.
    Suman, Vera J.
    Kuffel, Mary J.
    Haluska, Paul
    Reid, Joel M.
    Ames, Matthew M.
    CANCER RESEARCH, 2011, 71
  • [3] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Kathryn J. Ruddy
    Stephen D. Desantis
    Rebecca S. Gelman
    Alan H. B. Wu
    Rinaa S. Punglia
    Erica L. Mayer
    Sara M. Tolaney
    Eric P. Winer
    Ann H. Partridge
    Harold J. Burstein
    Breast Cancer Research and Treatment, 2013, 141 : 421 - 427
  • [5] Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Ruddy, Kathryn J.
    Desantis, Stephen D.
    Gelman, Rebecca S.
    Wu, Alan H. B.
    Punglia, Rinaa S.
    Mayer, Erica L.
    Tolaney, Sara M.
    Winer, Eric P.
    Partridge, Ann H.
    Burstein, Harold J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (03) : 421 - 427
  • [6] Complete disappearance of ER+/HER2+breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition
    Arpino, G
    Weiss, H
    Wakeling, AE
    Osborne, K
    Schiff, R
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S15 - S15
  • [7] CYP2D6 and CYP3A influence tamoxifen and endoxifen
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (05) : 524 - 525
  • [8] Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections
    Lee, Clara Inkyung
    Gurney, Howard
    CANCER FORUM, 2016, 40 (03) : 4 - 10
  • [9] Tamoxifen Resistance and CYP2D6 Copy Numbers in Breast Cancer Patients
    Motamedi, Sahar
    Majidzadeh, Keivan
    Mazaheri, Mahta
    Anbiaie, Robab
    Mortazavizadeh, Seyed Mohammad Reza
    Esmaeili, Rezvan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (12) : 6101 - 6104
  • [10] CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Berry, Donald
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17): : 1267 - 1269
12345